MAPT and Alzheimer disease: We discovered that immunization with monoclonal antibody 43D against Tau 6–18 reduced both Tau and Aβ pathologies, as well as rescued cognitive impairment in moderate to severe stages of Tau pathology in triple-transgenic AD (3 × Tg-AD) mice [18, 19].